FDA approve deferiprone (Ferriprox) for the treatment of transfusional iron overload due to sickle cell disease

A study that compared the efficacy of deferiprone to deferoxamine, in this patient population met the non-inferiority criterion for change in liver iron concentration from baseline after 12 months (14.93 at baseline to 12.30mg/g dw)

Source:

Biospace Inc.